Tag: pain

Nova Ukraine Earns 2025 Platinum Seal of Transparency from Candid

SAN FRANCISCO, July 3, 2025 /PRNewswire/ -- Nova Ukraine is proud to announce a new milestone: Platinum Seal of Transparency from Candid. This is the highest...

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Karolinska Development receives update from Organon concerning OG-6219

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate.

Arthro MD+ Joint Relief Cream Officially Launches: Natural Fast-Acting Solution in US, CA, UK, AU, NZ and IE

Arthro MD Cream launches in the US, Canada, UK, Australia, and Ireland, offering a science-backed, natural solution for joint pain and mobility. Fast-acting, non-greasy formula for seniors, athletes, and more.

Arthro MD Cream launches in the US, Canada, UK, Australia, and Ireland, offering a science-backed, natural solution for joint pain and mobility. Fast-acting, non-greasy formula for seniors, athletes, and more.

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer

Webexpenses launch Expense Cards setting new standards for seamless spend management

From purchase to pay, an all-in-one platform to enhance control that's free for all Webexpenses users. LONDON, July 2, 2025 /PRNewswire/ -- Webexpenses, a leading...

PXPay Plus Teams Up with foodpanda to Launch Taiwan’s First Integration of Electronic Payment and Food Delivery

A New Delivery Payment Ecosystem for All Ages and Scenarios — Enjoy Up to 10% Rewards for the Launch! TAIPEI, July 1, 2025 /PRNewswire/ --...

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

Ad hoc announcement pursuant to Art. 53 LR

T-Pain and Clinton Sparks Officially Launch the Global Gaming League in Las Vegas

The Star-Studded Kickoff Event Hosted by Nick Cannon and Jermaine Dupri featured a Performance by Social Media Pioneer Soulja Boy

 The Star-Studded Kickoff Event Hosted by Nick Cannon and Jermaine Dupri featured a Performance by Social Media Pioneer Soulja Boy

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)...

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsPain

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Diversified

Invitation to Vitrolife Group’s presentation of the Q2 2025 interim report

RedCloud Announces Pricing of $13.5 Million Private Placement of Securities